LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel ELISA Detects Invasive Aspergillosis

By LabMedica International staff writers
Posted on 05 Sep 2019
Print article
Image: Aspergillus (Photo courtesy of Kateryna Kon / Fotolia.com).
Image: Aspergillus (Photo courtesy of Kateryna Kon / Fotolia.com).
Aspergillus spp. is a ubiquitous sac fungus, which is found in soil or compost or on damp walls. Inhalation of spores can lead to severe infections in individuals with a weakened immune system.

In invasive aspergillosis (IA) the fungus spreads from the lungs to other parts of the body such as the nervous system, eyes, heart, kidneys and skin. Infections affecting the nervous system are nearly always fatal. Patients with neutropenia, leukaemia, or septic granulomatosis are especially at risk of IA.

Invasive aspergillosis is also a frequent complication in advanced AIDS or following chemotherapy or bone marrow or organ transplants. Early diagnosis and prompt treatment are crucial for survival. Since clinical and radiological signs of IA are often non-specific, additional diagnostics tests such as antigen detection and culture are nearly always required to substantiate diagnosis.

A CE-marked assay, Aspergillus Antigen ELISA (EUROIMMUN, Luebeck, Germany) is based on a monoclonal antibody for the detection of the Aspergillus-specific galactomannoprotein, which is produced during active fungal growth. The analysis is performed on patient serum or bronchoalveolar lavage (BAL) fluid. Results can be evaluated either quantitatively in pg/mL using a six-point calibration curve or semi-quantitatively by means of a cut-off ratio. Semi-automated processing is available, for example using the EUROIMMUN Analyzer I.

In the most comprehensive clinical study to date, carried out by the Ludwig-Maximilians-Universität München (Munich, Germany) based on 120 sera from 45 patients with proven IA as well as control sera, the EUROIMMUN Aspergillus Antigen ELISA yielded comparable sensitivity and specificity to another commercially available Aspergillus antigen test the Platelia Aspergillus Ag Assay. The EUROIMMUN assay identified 56% of the cases, while the Bio-Rad test detected 47%. The specificity amounted to 97% for the EUROIMMUN assay and 99% for the Bio-Rad test. To overcome the relatively low sensitivity of Aspergillus antigen detection, the authors recommend serial testing of patients at risk. The original study was published on June 25, 2019, in the Journal of Clinical Microbiology.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more